Trial Profile
A First in Human Phase 1 Study in Healthy Volunteers and in Participants With Frontotemporal Dementia (FTD) With Granulin Mutation
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Latozinemab (Primary)
- Indications Dementia
- Focus Adverse reactions; First in man
- Acronyms INFRONT
- Sponsors Alector
- 31 Jul 2020 Results presented at the Alzheimer's Association International Conference 2020
- 27 Jul 2020 According to a Quanterix media release, new findings from this study will be presented at the Alzheimer's Association International Conference (AAIC) 2020.
- 23 Jul 2020 Status changed from active, no longer recruiting to completed.